• HSD11 Assessing the Quality of Hemophilia Care: How Suitable Are Patient-Centered Outcomes to Compare Hospital Performance?

    Dec 1, 2025, 00:00

  • HTA207 Integrating Patient Perspectives Into Drug Reimbursement Decisions: Insights From Taiwan’s Deliberative HTA Process

    Dec 1, 2025, 00:00

  • EE266 Cost-Effectiveness of Perioperative Pembrolizumab for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Greece

    Dec 1, 2025, 00:00

  • MT16 Evaluating Digital Health Tools in the UK for Type 1/2 Diabetes: An Overview of the Evidence Critiques

    Dec 1, 2025, 00:00

  • SA72 Network Meta-Analysis of Survival Outcomes in the First-Line Treatment of Unresectable or Metastatic Melanoma: Scoping Review of Methodology

    Dec 1, 2025, 00:00

  • EE730 Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK

    Dec 1, 2025, 00:00

  • CO190 Prognostic Accuracy and Clinical Effectiveness of 68Ga-PSMA-11 PET/CT (ILLUCIX®) Imaging Followed by 177-Lu-PSMA-617 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO198 Quantifying the Therapeutic Benefit of External Beam Radiotherapy in Uterine Serous Carcinoma: A Real-World Study

    Dec 1, 2025, 00:00

  • Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum

    Dec 1, 2025, 00:00

  • EE147 Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?

    Dec 1, 2025, 00:00

  • EE405 Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel

    Dec 1, 2025, 00:00

  • EPH74 Epidemiological Burden of Osteoarthritis in Eastern, Central, and Western Europe Between 1990 and 2021

    Dec 1, 2025, 00:00

  • EE614 Preventing Stunting Through Early Nutritional Intervention: Effectiveness and Economic Evaluation in Children With Weight Faltering

    Dec 1, 2025, 00:00

  • MT38 Standardizing Healthtech Evidence to Meet NICE Expectations

    Dec 1, 2025, 00:00

  • EE394 Economic Evaluations of Medication Safety Interventions in Primary Care: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR103 From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany

    Dec 1, 2025, 00:00

  • EE712 The Impact of Burosumab on the Clinical and Economic Burden of X-Linked Hypophosphatemia in Adult Patients in France

    Dec 1, 2025, 00:00

  • EE351 Economic and Social Burden of Pulmonary Hypertension in Italy

    Dec 1, 2025, 00:00

  • HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

    Dec 1, 2025, 00:00

  • SA28 Decoding Diagnosis Delay in Juvenile Idiopathic Arthritis (JIA)

    Dec 1, 2025, 00:00

  • EE305 Cost-Utility Analysis of Multiplex Cell Culture Technology for Predicting Carboplatin Plus Paclitaxel-Induced Side Effects in Cancer Care

    Dec 1, 2025, 00:00

  • RWD146 Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE724 The Socioeconomic Burden of Dengue in Spain

    Dec 1, 2025, 00:00

  • HPR152 Orphan Drug Approvals in the US and Europe: A 2-Year Comparison

    Dec 1, 2025, 00:00

  • PCR207 Real-World Socioeconomic Burden and Health-Related Quality of Life (HRQoL) for Patients Living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the UK: Results From an Online Patient Survey

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • P16 Beyond PFS and OS: Recovering Pre- and Post-Progression Survival From Survival Curves

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • PT33 Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • EE548 Incorporating Environmental Impact Into Health Economic Evaluations: A Review of Methodological Approaches and Practical Applications

    Dec 1, 2025, 00:00

  • CO263 Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)

    Dec 1, 2025, 00:00

  • PCR174 Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • EPH260 Trends in Epidemiology and Mortality of Patients With Bladder Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2025, 00:00

  • EE303 Cost-Utility Analysis of Iptacopan vs. C5 Inhibitors in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Naïve to Complement Inhibitors in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • RWD57 Design Operating Characteristics in a Noninterventional Study Framework

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • HTA142 Evolving JCA Perspectives From EU Stakeholders and the Impact on Manufacturers

    Dec 1, 2025, 00:00

  • PT42 Comparative Effectiveness of Second-Line Antidiabetic Medications on the Risk of Major Adverse Cardiovascular Events: A Real-World Study in China

    Dec 1, 2025, 00:00

  • HTA287 Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • EPH93 Evaluating the Potential Health and Economic Impact of V116 vs. PCV20 on Invasive Pneumococcal Disease Among Adults in the United Kingdom

    Dec 1, 2025, 00:00

  • HTA325 The Perils of Treatment Crossover in Clinical Trials

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE426 Estimating the Economic Burden of DLBCL: Developing and Testing a Cost of Disease Model

    Dec 1, 2025, 00:00

  • EPH83 Epidemiology of Wilson's Disease in Europe: A Literature Review

    Dec 1, 2025, 00:00

  • HTA332 The Soft Science in Hard Decisions: Utility of Qualitative Evidence in HTA Decisions

    Dec 1, 2025, 00:00

  • HPR17 Advancing INN-Based Prescribing in Saudi Arabia’s Private Sector: Implications for Biologics and Biosimilars Utilization Under CHI Oversight

    Dec 1, 2025, 00:00

  • PCR127 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Myelodysplastic Syndromes (MDS)

    Dec 1, 2025, 00:00

  • HTA29 AI in Evidence Synthesis: Have We Reached the Promised Land or Are We Still Wandering the Desert?

    Dec 1, 2025, 00:00

  • MSR103 Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews

    Dec 1, 2025, 00:00

  • EE720 The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France

    Dec 1, 2025, 00:00

  • EE437 Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria

    Dec 1, 2025, 00:00

  • EPH179 Pharmacovigilance of Cannabis-Based Products in Brazil

    Dec 1, 2025, 00:00

  • EE286 Costs and Healthcare Resource Utilization Associated With Generalized Myasthenia Gravis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HSD103 Standardizing Point-of-Care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform

    Dec 1, 2025, 00:00

  • HTA199 Increased Trends of Self-Optimized Submissions to NICE

    Dec 1, 2025, 00:00

  • EE741 Understanding the Impact of the NICE Severity Modifier: A Targeted Review of Oncology Submissions

    Dec 1, 2025, 00:00

  • HPR66 Early Impact of the Mazars Review on Reimbursement Timelines in Ireland

    Dec 1, 2025, 00:00

  • EPH250 The Longevity Conundrum: Population Aging in the UK

    Dec 1, 2025, 00:00

  • EE533 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway

    Dec 1, 2025, 00:00

  • CO262 Utility of Minimum Dataset for Generation of Real-World Data in a Context With Evidence Gaps: The Left Ventricular Assist Devices as Destination Therapy

    Dec 1, 2025, 00:00

  • RWD100 Improving Access to German Health Claims Data Through Synthetic Data Generation: Findings and Achievements of a Holistic Evaluation

    Dec 1, 2025, 00:00

  • RWD88 Gender Inequalities in Aortic and Mitral Valve Interventions in Sweden

    Dec 1, 2025, 00:00

  • RWD34 Clinical Outcomes and Economic Burden of Acute Lower Respiratory Tract Infection-Related Hospitalizations Among Adults in the United States Post COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • CO89 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Breast Cancer: A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HPR186 Socioeconomic Disparities in Access to Treatment for Major Depressive Disorder: The Role of Accumulator and Maximizer Insurance Plans

    Dec 1, 2025, 00:00

  • MSR183 ROBERTA on the Job: A Proof-of-Concept Study of a Customized GPT Tool for Risk-of-Bias Assessment of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic

    Dec 1, 2025, 00:00

  • HTA50 Automated Excel-to-R Conversion of Health Economic Models Using the REEEVR Tool: Results of Alpha Test

    Dec 1, 2025, 00:00

  • OP5 Economic and Organizational Impact of Subcutaneous Ocrelizumab in French Daily Hospitals

    Dec 1, 2025, 00:00

  • HPR111 Harmonization of Drug Policy and Regulation Across Europe: A Comparison Between the European Medicines Agency and the European HTA Regulation

    Dec 1, 2025, 00:00

  • OP9 Gatekeepers of Scien Evolving Publishing Policies in the Age of AI

    Dec 1, 2025, 00:00

  • CO73 DII Mentoring Project— Patient Associations as a Catalyst for Quality-Of-Life Improvement and Positive Economic Impact in Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • SA17 Bigger, Better Studies: Prioritizing Literature Review Using an Approach Based on Large Language Models

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • RWD36 Clinical Humanistic and Economic Burden Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE463 Feasibility of Building a Generic Partitioned Survival Model for Oncology: Essential Components and Technical Implementation

    Dec 1, 2025, 00:00

  • MSR204 Transparent, Traceable, and Reproducible Evidence Generation for HTA Using Generative AI and Retrieval-Augmented Generation (RAG)

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • EE402 Economic Model of Alzheimer's Disease That Incorporates the Uncertainty Associated With Measuring Efficacy in Clinical Trials

    Dec 1, 2025, 00:00

  • CO122 Factors Associated With Response to Patient-Reported Outcome Measures: A Systematic Review of Systematic Reviews and Meta-analyses

    Dec 1, 2025, 00:00

  • CO7 Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments

    Dec 1, 2025, 00:00

  • PCR192 Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey

    Dec 1, 2025, 00:00

  • HPR61 Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease Hypertension and Diabetes

    Dec 1, 2025, 00:00

  • EE432 Evaluating the Acceptability of Vignette Studies in Eliciting Utility Values for Rare Diseases: Perspectives From European HTA Agencies

    Dec 1, 2025, 00:00

  • HTA154 From JCA to Local PR: Evaluating Impact Across Europe

    Dec 1, 2025, 00:00

  • MSR110 Flexible Parametric Inference for Cause-Specific Hazard-Competing Risk Models Under Interval Censoring

    Dec 1, 2025, 00:00

  • EE607 Persistence to Basal Insulin and Economic Outcomes Among Patients With Type 2 Diabetes: A Retrospective Analysis Using Electronic Health Records in England

    Dec 1, 2025, 00:00

  • P38 "Tell Me a Story": A Randomized Study Comparing Tabulated and Narrative Presentations of a Discrete Choice Experiment

    Dec 1, 2025, 00:00

  • PCR107 Health-Related Quality of Life Measured by EQ-5D Utility Among Patients With TGCT: A Trial-Based Analysis of EQ-5D Data From Patients in the MOTION Trial

    Dec 1, 2025, 00:00

  • HSD110 The Role of a Functional Clinical Staff in Guiding High-Cost Drug and Novel Technology Decision Making: Experience From a Latin American Oncology Clinic

    Dec 1, 2025, 00:00

  • EE252 Cost-Effectiveness of Genetic Testing for Optimizing Warfarin Therapy in Mechanical Heart Valve Patients: Insights From Qatar

    Dec 1, 2025, 00:00

  • PCR41 Changes in Physical Activity of Pediatric Patients Treated With Damoctocog Alfa Pegol During the Alfa-PROTECT Clinical Trial

    Dec 1, 2025, 00:00

  • EE428 Estimating the Public Health and Economic Impact of Recombinant Zoster Vaccine (RZV) Vaccination for Adults Aged 50 and Older in South Korea

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • EE184 Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom

    Dec 1, 2025, 00:00

  • HPR48 Comparative Analysis of Reimbursement Decisions for Advanced Oncology Combination Therapies in England and Japan

    Dec 1, 2025, 00:00

  • EE466 Financial Impact of Dementia Care on Thai Households: A Multicenter Study of Informal Care Costs and Contributing Factors

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • MSR223 When Excel Starts Talking Back: Unlocking the Power of Conversational AI for Health Economic Models

    Dec 1, 2025, 00:00

  • PCR227 The Economic Burden of Amyotrophic Lateral Sclerosis: An Observational Study of Out-of-Pocket Expenses and the Impact on Caregivers

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • HTA303 Structural Uncertainty (SU) in Model-Based Economics Appraisal (MBEA): A Document Review of the French National Authority for Health (HAS)

    Dec 1, 2025, 00:00

  • EPH196 Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries

    Dec 1, 2025, 00:00

  • HTA133 Evaluating the Impact of Implementing AI-Assisted Contouring on Radiotherapy Staff and Workflows

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • EE443 Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System

    Dec 1, 2025, 00:00

  • MSR112 From Evidence to Excel: Generative AI for Automated SLR Data Extractions

    Dec 1, 2025, 00:00

  • HTA172 Health Technologies Using Artificial Intelligen What Is Being Assessed in the UK by NICE?

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • CO75 Disease Progression Modeling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D)

    Dec 1, 2025, 00:00

  • EPH102 Expert Consensus on a Definition for Children With Medical Complexity in England: A Modified Delphi Panel

    Dec 1, 2025, 00:00

  • HTA68 Challenges and Opportunities in the Dutch Lock Procedure Improving Access and Reimbursement Timelines for Cell and Gene Therapies in the Netherlands

    Dec 1, 2025, 00:00

  • Cost-Effectiveness of Interventions Addressing Loneliness Among Adults: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA167 Guidelines for Health Technology Assessment Ministry of Health Sultanate of Oman

    Dec 1, 2025, 00:00

  • MSR142 Machine Learning to Predict Noncompliance and Program Dropout in Patients Treated for Chronic Diseases: Unsupervised and Supervised Analyses From a Large Multinational Drug Access Program Database

    Dec 1, 2025, 00:00

  • RWD4 A Real-World Retrospective Study on the Utilization of Antifibrotic Drugs in Greece During the Period 2019-2023

    Dec 1, 2025, 00:00

  • EE573 Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective

    Dec 1, 2025, 00:00

  • PT19 Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond

    Dec 1, 2025, 00:00

  • CO120 Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy

    Dec 1, 2025, 00:00

  • PCR246 Translation and Psychometric Validation of Brief Illness Perception Questionnaire: The Urdu Version

    Dec 1, 2025, 00:00

  • EE440 Evaluating the Economic Benefit of Improved High-Dose Influenza Vaccine Coverage in the Elderly Population of Tokyo, Japan

    Dec 1, 2025, 00:00

  • RWD168 Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis

    Dec 1, 2025, 00:00

  • EPH2 A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population

    Dec 1, 2025, 00:00

  • PCR204 Quantifying the Societal Burden of Acanthamoeba Keratitis: Results From a Patient Survey

    Dec 1, 2025, 00:00

  • MSR27 Analysis and Characterization of Variations in Conceptual and Operational Definitions for GLP-1 Agonist Treatment Eligibility for Weight Management

    Dec 1, 2025, 00:00

  • HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

    Dec 1, 2025, 00:00

  • EE304 Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

    Dec 1, 2025, 00:00

  • MSR65 Country-Specific Adaptation of Health Economic Models With Generative AI: A Case Study in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE564 Lessons From the NHS AI Awards: Experience of Evaluating AI Tools in Real-World Environments

    Dec 1, 2025, 00:00

  • EE572 Mapping the Use of Capability Measures ICECAP-A and O in Economic Evaluations

    Dec 1, 2025, 00:00

  • EE513 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • EE502 Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • EE648 Repeated Breast Surgery After a Lumpectomy in England

    Dec 1, 2025, 00:00

  • EPH141 Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data

    Dec 1, 2025, 00:00

  • EE251 Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK

    Dec 1, 2025, 00:00

  • EE354 Economic Burden and Unmet Need Among Adult Patients With Varying Patterns of Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • EE258 Cost-Effectiveness of Levofloxacin for Tuberculosis Prevention in MDR/RR-TB Contacts in High-Burden Settings

    Dec 1, 2025, 00:00

  • HPR50 Comparison of Alignment Between EMA Indications and National Reimbursement Decisions in Italy for Orphan Drugs

    Dec 1, 2025, 00:00

  • EPH257 Transition Across Cognitive States and Death Among Older Adults With Type 2 Diabetes: Determining the Predictors of Cognitive Decline With a Multistate Markov Model

    Dec 1, 2025, 00:00

  • EE605 Out-of-Pocket Expenditures of Families Affected by Epidermolysis Bullosa in Europe

    Dec 1, 2025, 00:00

  • CO156 Investigating Composite Response Definitions Based on Key Surrogate Markers for Predicting Clinical Outcomes in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR171 Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes, and Pathways

    Dec 1, 2025, 00:00

  • HPR121 Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch

    Dec 1, 2025, 00:00

  • EPH278 What Characteristics Are Associated With Having a Work Limitation Among United States Adults With Asthma?

    Dec 1, 2025, 00:00

  • HPR205 The Implementation of the European Charter of Patients’ Rights in Hungarian and Romanian Healthcare Legislation With Special Emphasis on Informed Consent

    Dec 1, 2025, 00:00

  • HPR4 A Comparative Analysis of Regulatory Divergence in Expedited Oncology Approvals: Evidence, Pathways, and Timelines Across FDA, EMA, TGA, and PMDA

    Dec 1, 2025, 00:00

  • EE399 Economic Impact of Incorporating a Fecal Bacterial Signature to Optimize FIT-Based Colorectal Cancer Screening in Spain

    Dec 1, 2025, 00:00

  • HPR80 Evolution of Manufacturer-Set List Prices and GKV Rebates for Orphan Drugs (OD) in Germany 2013-2024: How Much US WAC Is in German OD-Prices

    Dec 1, 2025, 00:00

  • CO143 Importance of Adjudication Committees in Retrospective Chart Review Studies for Outcomes Event Data Collection

    Dec 1, 2025, 00:00

  • HPR168 Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape

    Dec 1, 2025, 00:00

  • RWD155 Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act

    Dec 1, 2025, 00:00

  • PCR268 What Matters Most to Women in Breast Biopsy? A Discrete Choice Experiment in Italy

    Dec 1, 2025, 00:00

  • EPH191 Prevalence of Migraine in India: A Meta-Analysis With Subgroup Analyses by Population Type

    Dec 1, 2025, 00:00

  • CO236 The Clinical Burden and Complications Associated With Glycogen Storage Disease Type Ia (GSDIa): Results From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO9 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal-Bolus Insulin

    Dec 1, 2025, 00:00

  • CO207 Real-World Outcomes and Economic Impact of Ribociclib in HR+/HER2- Advanced Breast Cancer: Evidence From the Portuguese REASSURE Cohort

    Dec 1, 2025, 00:00

  • HPR238 What Does the New ILAP Refresh Mean for Pharmaceutical Development and Patient Access in the UK?

    Dec 1, 2025, 00:00

  • HTA155 From License to Reimbursement: A Slot-Based ML Framework for Seamless MA to HTA Alignment

    Dec 1, 2025, 00:00

  • EE112 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France

    Dec 1, 2025, 00:00

  • EE268 Cost-Effectiveness of Personalized Lifestyle Interventions in Obesity/Overweight: A Systematic Review

    Dec 1, 2025, 00:00

  • EE654 Risk, Time in Hospital, and Associated Costs? of Hospitalizations in Individuals With Infantile-Onset SMA: Results From DEVOTE Part B

    Dec 1, 2025, 00:00

  • EE550 Increased Healthcare Resource Utilization Among Uncontrolled vs. Controlled Hypertension Population: Findings From the EnligHTN Study

    Dec 1, 2025, 00:00

  • EE690 The Cost of Pressure: Quantifying the Consequences of Clinical Strain in Ophthalmology

    Dec 1, 2025, 00:00

  • MSR199 The HERC Database of Mapping Studies: A 2025 Update of a Live Systematic Review of Studies Predicting EQ-5D From Other Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • EPH63 Disease Burden of MASH/MASLD Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • HPR240 Who Pays the Price? International Impacts of US Drug-Cost Benchmarking

    Dec 1, 2025, 00:00

  • EPH116 Grounded Theory Study to Assess Barriers and Reasons for Insufficient Compliance With Valproate Risk Minimization Measures: Example of a Qualitative Method Aligned With the Recommendations of the GVP Module XVI, Addendum II

    Dec 1, 2025, 00:00

  • EPH199 Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom

    Dec 1, 2025, 00:00

  • EE125 Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology

    Dec 1, 2025, 00:00

  • HTA3 A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany

    Dec 1, 2025, 00:00

  • P22 Validation of Primary Care Resource Use and Costs in OMOP-Mapped vs. Source CPRD Aurum Data

    Dec 1, 2025, 00:00

  • EE685 The Artificial Intelligence Era in Health Economic Modeling

    Dec 1, 2025, 00:00

  • CO195 Qualitative Exit Interviews in Charcot-Marie-Tooth Type-2 Sorbitol Dehydrogenase (CMT-SORD) Deficiency

    Dec 1, 2025, 00:00

  • HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals

    Dec 1, 2025, 00:00

  • EPH9 A Systematic Literature Review to Identify Potential Risk Factors and Causative Organisms for Neonatal Sepsis in Indian Neonates

    Dec 1, 2025, 00:00

  • MSR184 Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Network Meta-Analysis Comparing Treatments to Paclitaxel

    Dec 1, 2025, 00:00

  • HPR164 Prices And Reimbursement Conditions for Poly (ADP-RIBOSE) Polymerase Inhibitors (PARPi) Indicated for Ovarian Cancer in Spain

    Dec 1, 2025, 00:00

  • SA49 Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model

    Dec 1, 2025, 00:00

  • HTA74 Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals

    Dec 1, 2025, 00:00

  • EE230 Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program

    Dec 1, 2025, 00:00

  • PCR187 Population-Level Impact of Emicizumab in Algeria: A 25-Year Projection

    Dec 1, 2025, 00:00

  • EE130 Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico

    Dec 1, 2025, 00:00

  • HTA12 A Retrospective Assessment of Drug Eligibility for NICE’s Highly Specialized Technologies Program Using the 2025 Criteria

    Dec 1, 2025, 00:00

  • MSR140 Machine Learning Applications in Treatment Pattern Analysis Using Real-World Data: A Scoping Review

    Dec 1, 2025, 00:00

  • CO258 US Population-Level Clinical Impact of Lorlatinib Treatment on ALK+ Metastatic Non-Small Cell Lung Cancer Outcomes

    Dec 1, 2025, 00:00

  • HPR65 Early Access Programs and Pricing and Reimbursement Agreements in Portugal for Orphan Medicines Centrally Approved in the European Union

    Dec 1, 2025, 00:00

  • HTA295 Routing Decisions and Outcomes of NICE Technology Appraisals Underproportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00

  • HTA104 Delayed Impact, Limited Leverage: Revenue Dynamics of Patent-Protected Drugs and the Effectiveness of Price-Volume Agreements in Germany

    Dec 1, 2025, 00:00

  • PCR233 The Impact of Treatment Compliance on Healthcare Resource Utilization Amongst Kidney Transplant Recipients: Results From a Real-World Survey

    Dec 1, 2025, 00:00

  • SA70 Modeling the Lifetime Effects of Lecanemab in Early Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • MSR87 Estimand Framework in the Setting of Observational Studies: Current Landscape and Future Directions

    Dec 1, 2025, 00:00

  • MSR63 Cost-Effectiveness Modeling Based on a Clinical Trial Re-analysis Using Multimodal Machine Artificial Intelligence Methodology: Predicting Which Patients May Benefit Most From the Addition of Tremelimumab to Durvalumab Plus Chemothera ...

    Dec 1, 2025, 00:00

  • SA94 The Impact of Early Antibacterial Therapy on ICU Patient Outcomes for Sepsis: A Causal Analysis

    Dec 1, 2025, 00:00

  • EE172 Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis

    Dec 1, 2025, 00:00

  • EE459 Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE696 The Costs of Loneliness-Related Health Consequences in Finland

    Dec 1, 2025, 00:00

  • HPR211 The Next Steps Matter? New Cancer Medicines and Their Indication Extensions in Europe 2010-2020

    Dec 1, 2025, 00:00

  • HTA90 Consideration of Off-Label Therapies as Appropriate Comparator Therapy in Early Benefit Assessments in Germany Under the ALBVVG Legislation

    Dec 1, 2025, 00:00

  • EE283 Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario

    Dec 1, 2025, 00:00

  • EPH187 Premature Mortality and Lost Productivity Due to HPV-Related Cancers in Europe

    Dec 1, 2025, 00:00

  • EPH210 Sedative-Hypnotic Drug Use and Polypharmacy Patterns Associated With Risk of Falls and Fractures in Older Adults by Osteoporosis Status: A Korean Nationwide Senior Cohort Study

    Dec 1, 2025, 00:00

  • PCR31 Bimekizumab Demonstrated Sustained Long-Term Improvements in Health-Related Quality of Life and Work Productivity in Patients With Active Psoriatic Arthritis: 3-Year Results from Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • RWD2 A Hierarchical Algorithm to Identify Pregnancy Start and Duration Using Structured EHR Data

    Dec 1, 2025, 00:00

  • HTA286 Reimbursement Trends for Advanced Therapeutic Medicinal Products (ATMPs) in Europe

    Dec 1, 2025, 00:00

  • MSR134 Interpreting PRO-CTCAE Data: Defining and Answering the Right Questions

    Dec 1, 2025, 00:00

  • MSR180 Reevaluating Cost-Effectiveness: A Holistic Framework for Assessing Disease-Modifying Treatments in Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HTA169 Harnessing Generative Artificial Intelligence for Global Value Dossier Development

    Dec 1, 2025, 00:00

  • PCR172 Patient Involvement in the Development of Obesity and Weight Loss-Specific Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • HTA222 Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024

    Dec 1, 2025, 00:00

  • HPR187 Socioeconomic Disparities in Postpartum Depression Following Abortion Restrictions: A Difference-in-Differences Analysis of Medicaid Data Post-Dobbs

    Dec 1, 2025, 00:00

  • EE151 Conceptualizing an Economic Model Structure for Parkinson's Disease

    Dec 1, 2025, 00:00

  • EPH142 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia Among United States Medicare Beneficiaries

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • EE153 Constructing a Dynamic Budget Impact Model: An AI Pretraining Approach for a New Parkinson's Disease Drug

    Dec 1, 2025, 00:00

  • PT17 Reconsidering Generic Utilities: Implications for Equitable Health Technology Appraisal

    Dec 1, 2025, 00:00

  • EE158 Cost Calculator of Immunotherapies in 1L Endometrial Cancer Treatment for the Deficient Mismatch Repair, Proficient Mismatch Repair, and Intention-to-Treat Populations From the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • HTA158 From Theory to Practi Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models

    Dec 1, 2025, 00:00

  • HSD26 Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

    Dec 1, 2025, 00:00

  • HTA276 Quality of Life and Productivity Costs in Cancer Patients Receiving Proton Therapy: A Predictive and Descriptive Study

    Dec 1, 2025, 00:00

  • HTA161 German Early Benefit Assessments and the Impact of Medical Societies: An Analysis

    Dec 1, 2025, 00:00

  • HPR172 Registration and Access to Orphan Medicines in Türkiye: A Comparative Study With Poland and Germany

    Dec 1, 2025, 00:00

  • HPR231 Unmet Need in IgA Nephropathy (IgAN): Disparity Between Clinical Guidelines and Real-World Practice in Ireland

    Dec 1, 2025, 00:00

  • PT24 Comparative Analysis of Early Scientific Advice Mechanisms: EU JSC vs. National HTA Bodies (HAS, G-BA, NICE)

    Dec 1, 2025, 00:00

  • EE395 Economic Evaluations Cost and Resource Utilization in Early Triple-Negative and Low Hormone Receptor-Positive Breast Cancer: A Comprehensive Systematic Review

    Dec 1, 2025, 00:00

  • HSD35 Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy

    Dec 1, 2025, 00:00

  • PCR245 To What Endpoint? Exploring Clinical Outcome Assessments of Pain in Phase 2 and 3 Trials and Drug Labels in Women’s Health Conditions

    Dec 1, 2025, 00:00

  • EE608 Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence

    Dec 1, 2025, 00:00

  • CO99 Epidemiology Treatment Patterns and Outcomes in Gestational Trophoblastic Neoplasia: A Systematic Literature Review and Gap Analysis

    Dec 1, 2025, 00:00

  • EPH95 Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)

    Dec 1, 2025, 00:00

  • HSD109 The Real-World Impact of Step Therapy and Prior Authorization on Patients, Clinicians, and US Health Plans: Lessons to Be Learned in Europe

    Dec 1, 2025, 00:00

  • EE388 Economic Evaluation of the Adoption of Peritoneal Dialysis for Newly Diagnosed Hemodialysis Ineligible Pediatric End-Stage Kidney Disease Patients in Egypt

    Dec 1, 2025, 00:00

  • EE347 Early Economic Modeling of Mutant TNF (mutTNF) As a BBB-Permeabilizing Adjunct in Breast Cancer Brain Metastases: A UK NHS Perspective

    Dec 1, 2025, 00:00

  • SA101 Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • HPR89 Facilitating Investment in Obesity Care and Prevention: A Societal Cost Benefit Analysis for the Netherlands

    Dec 1, 2025, 00:00

  • MSR46 Beyond the Mean: Do Distribution-Based Metrics Offer Greater Insight Into Predictors of Societal Health Preferences? A Secondary Analysis of 42 EQ-5D-5L Value Sets

    Dec 1, 2025, 00:00

  • PCR110 Health Utility Values in Adults With Primary Biliary Cholangitis: A Global Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR147 Is There a Lack of Dietary Data Collection in Real-World IBD Studies? Literature Review and Future Considerations

    Dec 1, 2025, 00:00

  • MSR71 Development of an A-Powered Command-Line Agent to Support Methodological Guidance Selection in Health Economics Analysis

    Dec 1, 2025, 00:00

  • CO72 Development of a Preliminary Conceptual Model to Capture the Adult Patient Experience of Follicular Lymphoma

    Dec 1, 2025, 00:00

  • EPH31 Budget Impact of an Organized Diabetes Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • P26 Approximating Competing Risk Events From Published Kaplan-Meier Curves Using Simultaneity-Based Event Assignment Methods

    Dec 1, 2025, 00:00

  • EE451 Examining the Opportunity Costs Due to Diabetic Macular Edema Taking Into Account Access Barriers Evaluated in the Barometer Program Survey in Colombia

    Dec 1, 2025, 00:00

  • MSR8 A Novel Framework to Assess Noninferiority in National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) Where Network Meta-Analyses (NMAs) Report Nonstatistically Significant Differences

    Dec 1, 2025, 00:00

  • HSD16 Burden of Disease and Healthcare Resource Use in Patients With Hereditary Transthyretin Amyloidosis in Spain: Findings From the OverTTuRe Global Study

    Dec 1, 2025, 00:00

  • PCR101 Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE630 Quantifying the Opportunity Costs of Intra-Direct Oral Anticoagulants (DOAC) Switching Pathways Across the National Health Service (NHS) in England: A Structured Framework

    Dec 1, 2025, 00:00

  • EE336 Discrete Event Simulation and Treatment Sequencing Cost-Effectiveness Model in Second-Line Highly Active Relapse Remitting Multiple Sclerosis for a NICE Multiple Technology Appraisal

    Dec 1, 2025, 00:00

  • MSR43 Automation-Only Is NOT AI: Beware, HEOR Colleagues

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • PCR220 Spillover Effects on Informal and Family Caregivers' Utility: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO114 Examining the Trade-off of Breastfeeding vs. Semaglutide Use After Childbirth

    Dec 1, 2025, 00:00

  • EE401 Economic Impact of Poison Control Center Interventions on Hospitalization Costs in Algeria: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • HPR237 Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections

    Dec 1, 2025, 00:00

  • SA96 The Use of Dynamic Models in Economic Evaluations in the UK and France

    Dec 1, 2025, 00:00

  • HPR139 Maximizing Profits Through Pricing: Opportunities in Portugal's Pharma Sector

    Dec 1, 2025, 00:00

  • CO254 Treatment Response in Pediatric Patients With Status Epilepticus: A Retrospective Observational Study From Saudi Arabia

    Dec 1, 2025, 00:00

  • HPR147 Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma

    Dec 1, 2025, 00:00

  • PCR87 Evolution of High-Efficacy Therapies for Relapsing Multiple Sclerosis: Does Innovation Meet Patient Preferences?

    Dec 1, 2025, 00:00

  • EPH225 Systematic Review on the Association of Loneliness and Social Isolation With Diabetes Mellitus

    Dec 1, 2025, 00:00

  • EPH264 Trends in the Number of Hospital Beds and Patient Turnover in Obstetrics and Gynecology in Hungary Between 2003 and 2023

    Dec 1, 2025, 00:00

  • RWD133 Parental Vaccine Hesitancy in Children With Comorbidities: A Comparative Analysis

    Dec 1, 2025, 00:00

  • MT30 Multi-Country Survey to Explore Clinicians Experiences on a New Imaging Technology for Gastrointestinal Endoscopes and Its Impact on Detection and Resection of Lesions

    Dec 1, 2025, 00:00

  • P34 Carbon Footprint Associated With Severe Asthma Care Before and After Benralizumab Initiation: BENEFIT Study

    Dec 1, 2025, 00:00

  • EE487 Health Economic Analysis of Malnutrition in the Netherlands

    Dec 1, 2025, 00:00

  • HPR44 Citizens’ Send Messages to Policy Makers Related to Primary Healthcare Practices: First Results From the Implementation of the Patient-Reported Indicator Surveys PaRIS in Greece

    Dec 1, 2025, 00:00

  • PCR185 Perspectives of Patients and Caregivers on Relapsed/Refractory Acute Myeloid Leukemia Treatments: A Mixed-Methods Interview Study

    Dec 1, 2025, 00:00

  • EE63 Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom

    Dec 1, 2025, 00:00

  • P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England

    Dec 1, 2025, 00:00

  • HTA10 A New Approach for Modeling the Complexity of the Impact of Caring Using the Family and Caregiving Effects

    Dec 1, 2025, 00:00

  • EE754 What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom

    Dec 1, 2025, 00:00

  • HPR79 Evolution in Hospital Bed Capacity in Hungary and Romania Between 1980 and 2020 With Special Focus on Regions Inhabited by Ethnic Minorities

    Dec 1, 2025, 00:00

  • MSR171 Prediction of Query Outcomes in the Setting of Observational Studies

    Dec 1, 2025, 00:00

  • EE644 Reducing the Transmission and Annual Burden of Influenza in the UK With Baloxavir Marboxil: A Cost-Effectiveness Analysis Using Evidence From the CENTERSTONE Trial

    Dec 1, 2025, 00:00

  • HPR29 Assessing Stakeholders’ Perceptions of the EU Health Technology Assessment Regulation and Access to Innovative Medicines in Europe and the Netherlands: Challenges, Opportunities, and Recommendations

    Dec 1, 2025, 00:00

  • RWD35 Clinical Relevance of a Machine Learning Model for Automated Analyses of Depression Severity: The ePHQ-9 in Treatment-Resistant Depression

    Dec 1, 2025, 00:00

  • HTA282 Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance

    Dec 1, 2025, 00:00

  • PCR136 Improving the Conceptual Coverage of the 15-item Penn Parkinson’s Daily Activity Questionnaire (PDAQ-15) for Use in the Mild-to-Moderate Lewy Body Dementia Population

    Dec 1, 2025, 00:00

  • HTA283 Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies

    Dec 1, 2025, 00:00

  • EE392 Economic Evaluations of Individual Service and Training Interventions for Self-Harm and Suicide Prevention: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR81 Effect of Positive Airway Pressure Therapy on Mortality in European Obstructive Sleep Apnea Patients: Post Hoc Analysis of a Global Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR140 Integrating Patient-Reported Outcome Measures and Patient Experience Into Health Technology Assessment: A Path Towards Patient-Centered Decision Making

    Dec 1, 2025, 00:00

  • EE561 Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease

    Dec 1, 2025, 00:00

  • CO208 Real-World Outcomes From a Pharmacy-Based Awareness and Screening Campaign for HF and CKD: Insights From the Chronic Diseases From A to Z Program

    Dec 1, 2025, 00:00

  • PT7 The Association Between Average Sales Price Decline and Shortages in Small Molecule Injectable Oncology Therapies With Generic Competition

    Dec 1, 2025, 00:00

  • HTA47 Assessment of Severity Modifiers vs. End-of-Life Criteria in Oncology

    Dec 1, 2025, 00:00

  • PCR249 Treatment Preferences in Adults With Chronic Spontaneous Urticaria in Italy: Insights From the CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • HTA102 Decoding the Future: How Are HTA Agencies Evaluating AI in Healthcare?

    Dec 1, 2025, 00:00

  • HTA204 Institutional Profiles and the Likelihood of Unfavorable Submissions in Public Consultations on Breast Cancer Drugs in Brazil’s Supplementary Health System

    Dec 1, 2025, 00:00

  • HTA100 Cost-Utility Analysis of Including X-linked Adrenoleukodystrophy in the Spanish Newborn Screening Program

    Dec 1, 2025, 00:00

  • PT1 A Contemporary Approach to Determining Cancer Patients Healthcare Resources Utilization

    Dec 1, 2025, 00:00

  • EE415 Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insuran A Case Study of Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • HPR39 Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective

    Dec 1, 2025, 00:00

  • HTA313 The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies

    Dec 1, 2025, 00:00

  • EPH70 Effects of Antidepressant Drug Classes on Dementia Risk: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Health Data

    Dec 1, 2025, 00:00

  • EPH12 An Exploration of the Incidence Rate of Anxiety and Depression Following a Diagnosis of Osteoarthritis Using the THIN Dataset

    Dec 1, 2025, 00:00

  • EPH195 Psychotropic Medications to Patients With Treatment-Resistant Depression in France

    Dec 1, 2025, 00:00

  • PCR176 Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy

    Dec 1, 2025, 00:00

  • PCR37 Capturing the Realities of Hematological Cancer Patients’ Experiences of Novel Immunotherapies: A Call for Alignment and Action to Improve PROM Within CAR-T and Bispecific Antibody Therapies

    Dec 1, 2025, 00:00

  • EPH43 Characterizing Polycystic Ovary Syndrome (PCOS) and Related Diagnoses Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025

    Dec 1, 2025, 00:00

  • HSD46 Evaluating the Digital Transformation in Healthcare: Adoption, Challenges, and Opportunities

    Dec 1, 2025, 00:00

  • RWD37 Comorbidities As a Risk Predictor of Kidney Disease Progression Among Patients Diagnosed With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • HTA36 Application of Budget Impact Model in Evaluation of P2P Payment Strategy in US Health Systems

    Dec 1, 2025, 00:00

  • MT23 Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • RWD162 Real-World Patient Characteristics and Outcomes Associated With Antibody Drug Conjugate Therapy: A Large Cohort Study

    Dec 1, 2025, 00:00

  • RWD72 Economic Burden of Prostate Cancer Overall and by Stages Based on the French Real-World Nationwide Medico-Administrative Database (SNDS)

    Dec 1, 2025, 00:00

  • EE82 Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • EE85 Budget Impact Analysis of GLP-1 Receptor Agonists for Type 2 Diabetes Management in India

    Dec 1, 2025, 00:00

  • EE478 Foregone Net Monetary Benefit From Underdiagnosis and Undertreatment of Mild Cognitive Impairment Due to Alzheimer’s Disease in the Medicare Population

    Dec 1, 2025, 00:00

  • HPR96 Fit-for-Purpose Real-World Data: Lessons From FDA QCARD and EMA Data Quality Framework

    Dec 1, 2025, 00:00

  • EE583 Model Structure Variability in NICE HTAs: Evidence From Asthma and TMA Appraisals to Support the Need for Disease-Specific Reference Models

    Dec 1, 2025, 00:00

  • HTA223 Limited Access to Joint Scientific Consultations in 2025: Strategic Impact on Industry and Policy Directions for Sustainable EU HTA Implementation

    Dec 1, 2025, 00:00

  • EE398 Economic Impact of Faricimab in Neovascular Age-Related Macular Degeneration Management in France

    Dec 1, 2025, 00:00

  • HTA323 The Landscape of the Use of Artificial Intelligence and Machine Learning (AIMI) Methods in Health Technology Assessment (HTA) Submissions

    Dec 1, 2025, 00:00

  • EE285 Costs and Health Outcomes of Meek Skin Micrografting vs. Mesh Skin Grafting in Adult Patients With Deep Partial Thickness and/or Full-Thickness Small (Burn) Wounds

    Dec 1, 2025, 00:00

  • EPH246 The Incidence Mortality and Survival of Malignant Hematopoietic Neoplasms in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HPR2 A Case Study: How England Implemented Its First Population Health Agreement

    Dec 1, 2025, 00:00

  • HTA294 Role of Technical Engagement in NICE Process Under Proportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00

  • EPH111 Five-Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • EPH112 Food and Health Literacy Among University Students: Sociodemographic Insights

    Dec 1, 2025, 00:00

  • HTA186 HTA League of Nations: Which Bodies Were Most Likely to Approve Submissions and for What Disease Areas?

    Dec 1, 2025, 00:00

  • SA67 Medical and Nonmedical Resource Utilization Associated With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics

    Dec 1, 2025, 00:00

  • EPH16 Analysis of the Epidemiological Disease Burden of Endometriosis in Hungary Based on Data From the Global Burden of Disease Study

    Dec 1, 2025, 00:00

  • PCR115 Health-Related Quality of Life for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • EE241 Cost-Effectiveness of ColonFlag in Austria: A Model-Based Evaluation

    Dec 1, 2025, 00:00

  • EE131 Clinical and Economic Impact of Hospital-Acquired Infections by Pseudomonas Aeruginosa in a Tertiary Care Teaching Hospital in India

    Dec 1, 2025, 00:00

  • EE416 Estimated Long-Term Healthcare Cost Savings From EVP Use in the UK

    Dec 1, 2025, 00:00

  • CO224 Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of Immunotherapies for Perioperative Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • HSD30 Current Treatment Pathway for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in England: Insights From a Qualitative Validation With Clinical Experts

    Dec 1, 2025, 00:00

  • HTA317 The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel

    Dec 1, 2025, 00:00

  • EE386 Economic Evaluation of Synovial Biopsy-Guided Treatment Strategy After TNF-Alpha Inhibitor Failure in Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • EE667 Socioeconomic Burden Among Children and Adults With Achondroplasia in Europe and Latin America

    Dec 1, 2025, 00:00

  • EE11 A Cost-Effectiveness Analysis of Ustekinumab Against Vedolizumab Among Inflammatory Bowel Disease Patients With Extra-intestinal Manifestations in Egypt

    Dec 1, 2025, 00:00

  • CO176 Pain-Related Disparities in Healthcare Expenditures Among Individuals With Cancer Evidence From the United States Medical Expenditure Panel Survey

    Dec 1, 2025, 00:00

  • HPR149 Negotiated Closed Budgets in Gree A Case Study of Success in Enhancing Patient Access Whilst Achieving Savings

    Dec 1, 2025, 00:00

  • HPR177 Review of Rare Disease Policy Developments in Europe and Türkiye 2020-2025 in the Context of Innovative Orphan Drugs

    Dec 1, 2025, 00:00

  • EPH42 Characteristics Associated With the Presence of a Functional Limitation Among Adults With Asthma in the United States: Findings From the Medical Expenditure Panel Survey Study

    Dec 1, 2025, 00:00

  • EE655 Saving Money Improving Outcomes: A Two-Year Cost-Utility Analysis of Emergency Department Care Models for Managing Persons Presenting With a Musculoskeletal Disorder

    Dec 1, 2025, 00:00

  • RWD153 Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions

    Dec 1, 2025, 00:00

  • EE673 Strategies for More Cost-Effective HrHPV Screening: A Simulation Study of Pooled Testing Based on Real-World Data in Low- and Middle-Income Countries

    Dec 1, 2025, 00:00

  • MSR40 Assessing Known Groups and Convergent Validity of the EQ-5D-5L in Assessing the Health-Related Quality of Life of Individuals With Obesity Who Have and Have Not Received Bariatric Surgery

    Dec 1, 2025, 00:00

  • EE602 Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

    Dec 1, 2025, 00:00

  • EE307 Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece

    Dec 1, 2025, 00:00

  • MSR228 Eliciting Health State Preferences With Analytical Hierarchy Process: An Illustration With EQ-5D-5L

    Dec 1, 2025, 00:00

  • HSD44 Environmental Impact of Psychiatric Outpatient Visit: Emissions Analysis of Travel and the Sustainability Potential of Remote Consultations

    Dec 1, 2025, 00:00

  • RWD106 Influencing Factors on the Health-Related Quality of Life of Middle-Aged and Elderly People in Ethnic Minority Areas of China: An Analysis Based on the Survey in a Urban Community of Guangxi Province

    Dec 1, 2025, 00:00

  • PCR131 Impact of Nontransfusion-Dependent Thalassemia on Adult Patients' Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • HPR150 Optimizing Pricing Models for Weight-Based and Multistock-Keeping Unit (SKU) Therapies in the EU4

    Dec 1, 2025, 00:00

  • SA90 Systematic Review of Doubly Robust Methods for Population-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EE379 Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil

    Dec 1, 2025, 00:00

  • EPH212 Severity of COVID-19 Pre- and Post-Omicron Emergence in Pediatric Patients: A Global Systematic Literature Review

    Dec 1, 2025, 00:00

  • MSR106 extRpolateS: A Shiny-Based Interactive Platform for Time-to-Event Data Modeling in Health Technology Assessments

    Dec 1, 2025, 00:00

  • CO244 The Incidence and Economic Impact of Major Adverse Events Associated With Intravascular Temperature Management: A Systematic Review, Analysis, and Model

    Dec 1, 2025, 00:00

  • PCR66 Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction

    Dec 1, 2025, 00:00

  • EE18 A Health Economic Evaluation Framework for Implementing a Digital Survivorship Passport for Childhood Cancer Survivors

    Dec 1, 2025, 00:00

  • EE108 Budget Impact of Introducing Accuchek® Smartguide Real-Time Continuous Glucose Monitoring (RtCGM) Solution for Diabetes Management in Portugal

    Dec 1, 2025, 00:00

  • PT37 Economic Evaluation of I-Medicine: An AI-Driven E-Medicine Platform for Reducing Adverse Drug Reactions and Healthcare Expenditures

    Dec 1, 2025, 00:00

  • EE118 Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study

    Dec 1, 2025, 00:00

  • HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System

    Dec 1, 2025, 00:00

  • EPH44 Chronic Kidney Disease in Type-2 Diabetes Patients: A Population-Based Descriptive Study

    Dec 1, 2025, 00:00

  • PCR237 The Mental Health Burden of Rare Diseases Based on Insights From Patients and Caregivers Through Rarepulse® Social Listening

    Dec 1, 2025, 00:00

  • HTA265 Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines

    Dec 1, 2025, 00:00

  • PCR235 The Life With Amyotrophic Lateral Sclerosis: Socioeconomic Impact of the Disease on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2025, 00:00

  • CO154 Infective Endocarditis Following FRANCE-TAVI Insights

    Dec 1, 2025, 00:00

  • HTA105 Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals

    Dec 1, 2025, 00:00

  • HPR180 Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care

    Dec 1, 2025, 00:00

  • HPR148 Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • RWD149 Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • P12 Work Productivity Loss in Individuals Due to Respiratory Infections: A Questionnaire Survey of Employees in Denmark

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • P36 The Value of the Health and Well-being Benefits of Healthcare Facilities Outdoor Spaces

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • EE732 To Be or Not to Be Willing to Pay

    Dec 1, 2025, 00:00

  • HTA165 Global Adoption of Dynamic Transmission Models in Infectious Disease Vaccine Submissions: A Comparative Analysis Across the EU5 North America and Scandinavia

    Dec 1, 2025, 00:00

  • EPH149 Integrated Sustainability Assessment of the Population-Based Colorectal Cancer Screening Program in Flanders

    Dec 1, 2025, 00:00

  • SA83 Real-World Utilization Patterns of Corticosteroids in Ulcerative Colitis: Prevalence of Excessive Use in Routine Clinical Practice

    Dec 1, 2025, 00:00

  • CO175 Overall Treatment Landscape of Mucosal Melanoma

    Dec 1, 2025, 00:00

  • EE133 Clinical Management and Outcomes of Patients in England With eGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Observational Study and Its Impact on UK Health Technology Assessments

    Dec 1, 2025, 00:00

  • HTA300 Simulating PICOs to Predict Evidence Requirement Implications of the EU Joint Clinical Assessment: Learnings From 24 Case Studies

    Dec 1, 2025, 00:00

  • HPR128 International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024

    Dec 1, 2025, 00:00

  • P6 Potential Modifiers of Cost-Effectiveness Thresholds: Public Perspectives on Prioritization in Healthcare Spending

    Dec 1, 2025, 00:00

  • RWD6 A Record-Level Risk Metric for Partially Synthetic Clinical Data Using Inverse-Square Similarity Decay

    Dec 1, 2025, 00:00

  • EE369 Economic Consequences of Disease-Related Malnutrition in Poland and the Potential Cost Savings From Nutritional Interventions: A Two-Step Modeling Study

    Dec 1, 2025, 00:00

  • RWD137 Prevalence Utilization Patterns and Economic Impact of eGFR and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Real-World Analysis From Greece

    Dec 1, 2025, 00:00

  • P54 Thus SPOKE the TA: Querying NICE Technology Assessments Using Generative AI and RAG

    Dec 1, 2025, 00:00

  • HTA339 Transparency Tested: Conflict of Interest in EU HTA

    Dec 1, 2025, 00:00

  • PCR167 Outcome Measures Relevant for Assessing Health-Related Quality of Life and Utility in Primary Lateral Sclerosis (PLS)

    Dec 1, 2025, 00:00

  • MSR203 Traditional vs. Generative AI: A Rapid Systematic Review Assessing Accuracy and Efficiency of AI in Title/Abstract Screening

    Dec 1, 2025, 00:00

  • EE83 Budget Impact Analysis of Early FGFR3 Testing in Metastatic Urothelial Carcinoma: A Finnish Healthcare Perspective

    Dec 1, 2025, 00:00

  • EE66 Assessing Treatment Efficiency Indicated in Rare Diseases: Learning From the CEESP Has Economic Opinions

    Dec 1, 2025, 00:00

  • HTA72 Challenges in Predicting the Joint Clinical Assessment (JCA) Scope From a Stakeholder Perspective: A Case Study in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »